Lupin Limited announced that the company’s US-based wholly-owned subsidiary Lupin Pharmaceuticals Inc. has entered into an agreement with ForDoz Pharma Corp (ForDoz).

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.

The consolidated net sales reported in Q1FY21 came in at Rs 3,527.86 crore, which declined by 9.02 per cent YoY from Rs 3,877.69 crore in Q1FY20. 

As markets witnessed a strong rebound from lower levels and closed above the 11,200 level, the 'buy on dip' strategy worked quite well on Thursday's session.  On Friday, cues from Asian peers are mostly negative and hence, today's session is likely to begin on a cautious note.

As the daily bars are making higher highs and higher lows, it is better to continue the long positions with a trailing stop-loss. Stocks in news: Prince Pipes and Fittings, SML ISUZU, Jubilant FoodWorks, TCS, Lupin, Wipro.

The consolidated net sales reported in Q1FY21 came in at Rs 10,659.3 crore, which   declined by 5.42 per cent YoY from Rs 11,269.9 crore in Q1FY20.

The shares of GOCL Corporation Limited, a Hinduja Group Company, climbed by 20 per cent on Thursday, hitting the upper circuit after the company posted encouraging results for the quarter ended June 2020.

Tata Group companies are buzzing on the bourses. At least 10 out of 17 companies of the Group have outperformed Sensex, taking into consideration the market movement since July 1, 2020.

On Thursday, with RBI's announcement of keeping the repo rate unchanged at four per cent, Sensex rose by 362.12 points or by 0.96 per cent to close at 38,025.45 while its NSE counterpart Nifty gained by 98.50 points or 0.89 per cent to end at 11,200.15.

Lupin Limited announced on Thursday that it has received approval from United States Food and Drug Administration (USFDA) for Mycophenolate Mofetil tablets USP, 500 mg, to market a generic version of CellCept® tablets of Roche Palo Alto LLC (Roche) in alliance with Concord Biotech Limited.